Subcutaneous Rituximab Shows Similar Efficacy, Lower Cost in Non-Hodgkin Lymphoma
• A meta-analysis of 7 studies showed subcutaneous rituximab had similar efficacy to intravenous rituximab in non-Hodgkin lymphoma patients.
• The analysis found no significant difference in grade 3 or higher adverse events between subcutaneous and intravenous rituximab.
• Subcutaneous rituximab was associated with lower total costs, pharmacy technique costs, and administration costs compared to intravenous rituximab.
• Subcutaneous rituximab also demonstrated a lower total process time, suggesting increased efficiency in administration.
© Copyright 2025. All Rights Reserved by MedPath